Form 4: Pelthos Therapeutics Director Granted Equity Awards Following Reverse Stock Split

Pelthos Therapeutics Director Todd C. Davis received grants of restricted stock units and stock options totaling 77,338 shares at an exercise price of $13.50, following a 1-for-10 reverse stock split.

Summary

• Todd C. Davis, a Director of Pelthos Therapeutics Inc. (PTHS), was granted equity awards on July 2, 2025.
• The grants include 19,108 restricted stock units (RSUs) and 58,230 stock options, both with an exercise price of $13.50 per share.
• Both the RSUs and stock options are set to vest on a quarterly basis over a period of three years, commencing July 2, 2026, and expiring on July 2, 2035.
• The reported numbers for beneficial ownership have been adjusted to reflect a 1-for-10 reverse stock split effected by Pelthos Therapeutics Inc. on July 1, 2025.
• Following these transactions, Todd C. Davis beneficially owns 36,969 restricted stock units and 58,230 stock options.

Sentiment

Score: 5

Explanation: The document is a factual report of an insider equity grant, which is a routine compensation event and does not inherently convey positive or negative sentiment about company performance.

Positives

• The granting of equity awards (Restricted Stock Units and Stock Options) to Director Todd C. Davis aligns his interests with long-term shareholder value.
• The three-year quarterly vesting schedule encourages long-term commitment and performance from the director.

Future Outlook

The granted restricted stock units and stock options will vest on a quarterly basis over a period of three years, indicating a future alignment of the director's incentives with long-term company performance.

Industry Context

This document is a standard SEC Form 4 filing, which reports changes in beneficial ownership of company securities by insiders. It reflects a routine equity compensation event for a director and does not provide broader industry context or trends.

Related Party Transactions

• Grant of 19,108 restricted stock units and 58,230 stock options to Todd C. Davis, a Director of Pelthos Therapeutics Inc., as part of his compensation.

Stakeholder Impact

• Shareholders: Potential future dilution from the exercise of these equity awards, but also increased alignment of director's interests with long-term shareholder value through performance-based compensation.
• Employees: No direct impact on general employees is indicated by this specific director compensation filing.

Next Steps

• Quarterly vesting of the 19,108 restricted stock units and 58,230 stock options over a three-year period, commencing July 2, 2026.

Key Dates

Keywords

Pelthos Therapeutics, PTHS, SEC Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Director Compensation, Reverse Stock Split